IDEXX Laboratories, Inc. (FRA:IX1)

Market Cap	45.06B +33.9%
Revenue (ttm)	3.55B +8.4%
Net Income	875.67M +18.6%
EPS	10.74 +21.6%
Shares Out	n/a
PE Ratio	51.46
Forward PE	47.77
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	8
Open	571.40
Previous Close	580.20
Day's Range	571.40 - 571.40
52-Week Range	325.20 - 665.80
Beta	n/a
RSI	32.60
Earnings Date	Feb 2, 2026

About IDEXX Laboratories

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1983
• Employees: 11,000
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: IX1

Financial Performance

In 2024, IDEXX Laboratories's revenue was $3.90 billion, an increase of 6.46% compared to the previous year's $3.66 billion. Earnings were $887.87 million, an increase of 5.07%.

Financial numbers in USD